Martin Reck
机构: LungenClinic, Deutsches Zentrum für Lungenforschung
每年引用次数
引用次数
引用: 109,628
H-指数: 123
I10-指数 : 535
出版物: 1,454
580_PR: Clinical and demographic features that influence EGFR mutation detection in plasma from patients (pts) with aNSCLC: The ASSESS experience
N. Normanno , H. Brown , V. Haddad , M. Ratcliffe
Journal of Thoracic Oncology 11 ( 4)
2
2016
134PD Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150)
M. Reck , M.A. Socinski , F. Cappuzzo , F. Orlandi
Journal of Thoracic Oncology 13 ( 4)
3
2018
188P Treatment switching–adjusted overall survival (OS) in KEYNOTE-024: First-line pembrolizumab versus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
M. Reck , D. Rodríguez-Abreu , A.G. Robinson , R. Hui
Journal of Thoracic Oncology 13 ( 4)
1
2018
1371P Diagnostic and therapeutic strategies for elderly patients with advanced non-small cell lung cancer (NSCLC): results from an EORTC pan-European survey.
M. Giaj Levra , J. Menis , A. Luciani , E. De Maio
Annals of Oncology 28
2017
Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis
S. Peters , S.S. Ramalingam , L. Paz-Ares , R. Bernabe Caro
Annals of Oncology 30
31
2019
Patient-focused outcomes in RELAY, a phase III trial of ramucirumab plus erlotinib (RamErl) versus placebo plus ERL (PboErl) in untreated EGFR-mutated metastatic NSCLC (EGFR+ mNSCLC)
K. Yoh , S. Atagi , M. Reck , E.B. Garon
Annals of Oncology 30
2019
Nintedanib (N) + docetaxel (D) after immunotherapy in adenocarcinoma non-small cell lung cancer (NSCLC): First results from the non-interventional LUME-BioNIS study
M. Reck , K. Syrigos , S. Miliauskas , S. Zöchbauer-Müller
Annals of Oncology 30
2019
127TiP PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours
M. Reck , F. Cappuzzo , D. Rodriguez-Abreu , D.C. Cho
Annals of Oncology 30
2019
KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
S. Gadgeel , D. Rodriguez-Abreu , E. Felip , E. Esteban
Annals of Oncology 30
12
2019
LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis
L. Paz-Ares , T.E. Ciuleanu , X. Yu , P. Salman
Annals of Oncology 30
48
2019
Vinorelbine (NVB)-carboplatin (CBDCA) vs non-platinum doublets in inoperable non-small cell lung cancer (NSCLC) patients (pts)-final results of the Glob 2 phase III with patient benefit analysis
R. P. Abratt , A. Szczesna , K. Mattson , M. Wernli
Journal of Clinical Oncology 22 7016 -7016
9
2004
Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
I. Watermann , B. Schmitt , F. Stellmacher , J. Müller
Diagnostic Pathology 10 ( 1) 130 -130
49
2015
[Updated Recommendation for Treatment of Metastatic Non-Small Cell Lung Cancer].
N. Reinmuth , A. Gröschel , C. Schumann , M. Sebastian
Pneumologie 72 ( 2) 138 -154
4
2017
Pharmacogenomics in NSCLC: mostly unsexy but desperately needed
B. Besse , M. Reck
Annals of Oncology 25 ( 11) 2099 -2100
1
2014
Biomarker analysis in a phase III study of pemetrexed–carboplatin versus etoposide–carboplatin in chemonaive patients with extensive-stage small-cell lung cancer
E.F. Smit , M.A. Socinski , B.P. Mullaney , S.P. Myrand
Annals of Oncology 23 ( 7) 1723 -1729
26
2012
What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
M. Reck
Annals of Oncology 23
43
2012
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
M. Reck , I. Bondarenko , A. Luft , P. Serwatowski
Annals of Oncology 24 ( 1) 75 -83
674
2013
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Peters , A.A. Adjei , C. Gridelli , M. Reck
Annals of Oncology 25 27 -39
762
2012
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)
S. Ramalingam , J. Crawford , A. Chang , C. Manegold
Annals of Oncology 24 ( 11) 2875 -2880
35
2013
Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
J.H. Kim , M.J. Ahn , M. Reck , A. Pazzola
Annals of Oncology 25 ( 5) 1044 -1052
115
2014